Nextech Invest
Jakob Loven, Ph.D., is a partner at Nextech Invest Ltd. An accomplished oncology-focused entrepreneur and life science venture capitalist, Jakob brings to Nextech his extensive experience in creating, launching and building early stage therapeutic-based platform biotechnology companies, including Relay Therapeutics and Syros Pharmaceuticals (NASDAQ: SYRS).
Today, Jakob serves as a board member of A2 Biotherapeutics, Vividion, Arrakis, Kronos (NASDAQ:KRON) and IconOVir. He is a former board member of Arvinas (NASDAQ: ARVN), and board observer of Kinnate (NASDAQ:KNTE), Turning Point Therapeutics (NASDAQ: TPTX) and Autolus (NASDAQ: AUTL).
Jakob earned his Ph.D. in medical sciences focused on oncology from Karolinska Institutet and earned his B.A. in biomedical sciences in the UK.
This person is not in any offices
Nextech Invest
Nextech is a global, cancer therapeutics-focused venture capital firm headquartered in Zurich, Switzerland. They focus almost exclusively on oncology therapeutics, and on helping to drive value creation for their portfolio companies. They invest in the most promising drug discovery companies with the potential to create multiple medicines. Their portfolio is focused throughout the US and Europe with investments from company inceptions to crossover rounds.